ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma

  • Yanjiao Mao, Shixiu Wu
  • OncoTargets and Therapy, July 2017, Dove Medical Press
  • DOI: 10.2147/ott.s133349

The authors haven't yet claimed this publication.

open access logoRead Publication

http://dx.doi.org/10.2147/ott.s133349